Conducting Clinical Trials of the Medicine "Rutan Tablets 0.1g" No. 10 in the Complex Therapy of COVID-19
Status:
Completed
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to evaluate the efficacy and safety of the registered
drug Rutan 0.1 against SARS-CoV-2 in patients with COVID-19.
The main group (30 people) - patients with COVID-19 who are on inpatient treatment who were
prescribed the drug Rutan 0.1, 1 tablet 2 times a day for 10 days.
The control group (27 people) - patients with COVID-19 who are hospitalized and received
therapy according to the National Temporary Protocol for the management of patients with
COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan